pSivida Corp

Press Releases

All Releases
View Summary pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA
Jan 8, 2018
PDF 17.7 KB Add to Briefcase
View Summary pSivida Granted Waiver by the FDA for New Drug Application Filing Fee
Jan 4, 2018
PDF 14.7 KB Add to Briefcase
View Summary pSivida to Present at the Annual Biotech Showcase Conference
Jan 2, 2018
PDF 12.2 KB Add to Briefcase
View Summary HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data
Dec 14, 2017
PDF 20.2 KB Add to Briefcase
View Summary pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution
Nov 7, 2017
PDF 27.7 KB Add to Briefcase
View Summary pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Oct 18, 2017
PDF 14.6 KB Add to Briefcase
View Summary pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma
Oct 10, 2017
PDF 25.8 KB Add to Briefcase
View Summary pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs
Sep 26, 2017
PDF 16.6 KB Add to Briefcase
View Summary pSivida to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Sep 22, 2017
PDF 13.1 KB Add to Briefcase
View Summary pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results
Sep 11, 2017
PDF 34.1 KB Add to Briefcase
View Summary pSivida to Present at Rodman & Renshaw Annual Global Investment Conference
Sep 11, 2017
PDF 13.4 KB Add to Briefcase
View Summary pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th
Sep 5, 2017
PDF 13.8 KB Add to Briefcase
View Summary pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017
Aug 1, 2017
PDF 13.0 KB Add to Briefcase
View Summary Leading Retinal Specialists to Highlight pSivida's Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences
Jul 18, 2017
PDF 20.6 KB Add to Briefcase
View Summary pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSivida's Revenue Generation
Jul 10, 2017
PDF 25.6 KB Add to Briefcase
View Summary pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson
Jun 28, 2017
PDF 17.1 KB Add to Briefcase
View Summary pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert™ Three-year Treatment for Posterior Segment Uveitis in the European Union
Jun 22, 2017
PDF 21.0 KB Add to Briefcase
View Summary pSivida's Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study
Jun 13, 2017
PDF 22.5 KB Add to Briefcase
View Summary Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months
May 8, 2017
PDF 21.0 KB Add to Briefcase
View Summary pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track
May 4, 2017
PDF 38.7 KB Add to Briefcase
Showing 1-20 of 291 Page: 1 2 3 4 5 ... 15  Next 20
Add to Briefcase = add release to Briefcase

Search Investor Relations

pSivida